Email not displaying correctly? View it in your browser.
November 2017
http://medprofvideos.mayoclinic.org/videos/proton-therapy-has-advantages-over-imrt-for-advanced-head-and-neck-cancers

Patient Care

Mayo Clinic offers CAR T-cell therapy for B-cell non-Hodgkin's lymphoma
Mayo Clinic's campus in Rochester, Minnesota, now provides chimeric antigen receptor T-cell therapy (CAR T-cell therapy) for adults with B-cell non-Hodgkin's lymphoma who have not responded to, or have relapsed after, two or more lines of treatment.

Awake craniotomy offers better outcomes for patients with tumors in eloquent motor and sensory tissue
Mayo neurosurgeons have successfully expanded their use of awake craniotomy from the removal of tumors in the cortical speech area of the brain to areas of eloquent motor and sensory tissue.


HPV test for cervical cancer reduces screening frequency
Certain forms of HPV are responsible for most cases of cervical cancer. If a test shows the virus is not present and cervical cells are normal, most healthy women won't need another screening test for three to five years.

Mayo cyclotron facilities improve treatment for prostate cancer
Manufactured as needed and injected into a vein, the radioactive nutrient C-11 choline concentrates where cancer is present and is visible by PET scan. The exam allows specialists to detect prostate cancer years before other forms of imaging.

Research

Z-endofixen shrinks tumors safely in women with estrogen receptor positive metastatic breast cancer
In a study of patients with endocrine-refractory metastatic breast cancer, Z-endoxifen provided substantial drug exposure unaffected by CYP2D6 metabolism, acceptable toxicity and promising anti-tumor activity.

Researchers explore the role of fatty acid synthase in cancer development
Mayo researchers are studying genes that are highly expressed in cancerous tissue but not in normal tissue and examining the cause and effect of fatty acid synthase in the cancer cell to identify a process to starve cancer.

Cyst fluid biomarkers increase detection of early pancreatic cancer
In a study of a panel of new DNA methylation markers assayed from the pancreatic cysts of 134 patients, detection accuracy was significantly higher than currently available markers. These markers may help avoid unnecessary surgical intervention and improve patient outcomes.

See all Cancer Clinical Trials at Mayo Clinic

Back to Top

Education

Mayo Clinic Radiation Oncology: Current Practice and Future Direction 2018
Jan. 8-12, 2018, in Maui, Hawaii
Topics include breast, prostate and central nervous system cancers, lymphoma, and sarcomas. This course covers management strategies and surgical options for prostate-specific antigen failure of prostate cancer, the future of prostate brachytherapy, and radiotherapy for early-stage breast cancer.


Advances in Breast Cancer Management 2018
Feb. 9-10, 2018, in Ponte Vedra Beach, Fla.
Course focus includes imaging, radiation therapy, brain metastases, genomic testing, systemic therapy and survivorship for patients with early- and advanced stage breast cancer. Experts address the role of the immune system, review novel immunotherapies, and discuss clinical controversies and challenges.


Mayo Clinic Gastrointestinal Cancers 2018 — Current and Emerging Strategies in Multidisciplinary Care: Translating Evidence into Best Practices

March 1-3, 2018, in San Diego
This course addresses best and most-current evidence in the routine care of patients with these gastrointestinal cancers: esophageal, gastric, hepatocellular, pancreatic, small bowel, bile duct, anal and colorectal, and gallbladder.


See all Hematology and Oncology Continuous Professional Development courses

In the Video Center

New Tumor-Shrinking Nanoparticle to Fight Cancer, Prevent Recurrence
Betty Y S (Betty) Kim, M.D., Ph.D., discusses a new type of cancer-fighting nanoparticle that produced potent anti-tumor immune responses to HER2-positive breast cancers. Mice treated with these nanoparticles also showed resistance to future tumor recurrence.

Therapy for Relapsed Multiple Myeloma
David Dingli, M.D., Ph.D., discusses the increasing number of effective therapeutic agents available for treatment of multiple myeloma. Combination therapy with non-cross-resistant and synergistic combinations are leading to deeper and longer responses and translating into improved survival for this disease.

View videos by specialty and Grand Rounds presentations online

Back to Top

Consults & Referrals

Connect With Us

Facebook iconTwitter iconYoutube icon


Receive real-time news and thought-leading insight

Back to Top

 
 
 
Mayo Clinic
13400 E. Shea Blvd.
Scottsdale, AZ 85259

4500 San Pablo Road
Jacksonville, FL 32224

200 First St. SW
Rochester, MN 55905